Basis of Presentation - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Inventory [Line Items]
Inventory	$ 14,744		$ 18,515
Accumulated Deficit	234,625		222,758
Proceeds from issuance of preferred stock	30,000	$ 0
Customers For Which Returns Are Expected To Be Received
Inventory [Line Items]
Accrued sales returns resulting from FDA Warning Letter	$ 3,407		$ 4,958